LeonaBio, Inc. - Asset Resilience Ratio
LeonaBio, Inc. (LONA) has an Asset Resilience Ratio of 48.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how LeonaBio, Inc.'s Asset Resilience Ratio has changed over time. Check asset allocation strategy of LeonaBio, Inc. to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down LeonaBio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of LeonaBio, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.85 Million | 48.67% |
| Total Liquid Assets | $34.85 Million | 48.67% |
Asset Resilience Insights
- Very High Liquidity: LeonaBio, Inc. maintains exceptional liquid asset reserves at 48.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
LeonaBio, Inc. Industry Peers by Asset Resilience Ratio
Compare LeonaBio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for LeonaBio, Inc. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for LeonaBio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.68% | $19.05 Million | $92.15 Million | +15.85pp |
| 2024-12-31 | 4.83% | $2.84 Million | $58.78 Million | -30.64pp |
| 2023-12-31 | 35.47% | $56.84 Million | $160.25 Million | -4.97pp |
| 2022-12-31 | 40.43% | $104.38 Million | $258.15 Million | -2.71pp |
| 2021-12-31 | 43.14% | $143.22 Million | $332.01 Million | -1.24pp |
| 2020-12-31 | 44.38% | $124.06 Million | $279.56 Million | +13.97pp |
| 2018-12-31 | 30.41% | $1.50 Million | $4.93 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more